Forum Arrowhead Research geopend

2.405 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 117 118 119 120 121 » | Laatste
drulletje drie
0
2019 will be productive

Expect 2 new CTAs
• ARO-HIF2
• ARO-ENaC
• Expect to be in Phase 2 or later with 3 wholly-owned candidates
• ARO-AAT, ARO-ANG3, ARO-APOC3
• Expect progress with partnered clinical candidates
• ARO-HBV, AMG 890
• Wildcards
• New Janssen targets
• Amgen undisclosed CV target
• Muscle targeting
• ARWR breakthroughs

ir.arrowheadpharma.com/static-files/a...

Roofer
0
Flinke dalingen recentelijk.

Mogelijkheid voor rebounce naar 17$ juist, of wachten tot de $10,-?

Ik snap niet zo goed waarom, lijkt mij een fundament liggen dankzij J&J.
drulletje drie
0
quote:

Roofer schreef op 20 november 2018 15:46:


Flinke dalingen recentelijk.

Mogelijkheid voor rebounce naar 17$ juist, of wachten tot de $10,-?

Ik snap niet zo goed waarom, lijkt mij een fundament liggen dankzij J&J.


Heb je de rest van de markten gezien laatste dagen?
Dan snap ik wel waarom hoor! Ook de bio gaat dan gewoon mee omlaag dus geen idee hoever het nog kan dalen! J&J is een mooi bericht maar zullen gewoon goede onderzoeksresultaten moeten komen om de $ 20.00 plus op de borden te krijgen.
Tom3
0
www.nasdaq.com/symbol/arwr/institutio...

Flinke uitbreiding door institutionele beleggers. Er breekt nu waarschijnlijk paniek uit bij de shorts ( ca 17 miljoen). Stijging is nu al 5% Op naar de $ 20 zou ik zeggen.
Tom3
0
Straks moet Intellia nog aankloppen bij Arrowhead voor gebruikmaking van het Trim platform. Bij de Crispr-Cas9 bedrijven bestaat de nijpende noodzaak voor een aangepast vehikel om de dna segmenten veilig een cel in te krijgen:

www.ncbi.nlm.nih.gov/pmc/articles/PMC...
sp1946
0
Tís maar dat u het weet:

Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00 at Cantor Fitzgerald
Posted by ABMN Staff on Dec 17th, 2018 //
DeZwarteRidder
0
Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00

Posted by Lisa Matthews on Dec 17th, 2018

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price upped by stock analysts at Cantor Fitzgerald from $145.00 to $165.00 in a report issued on Monday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. Chardan Capital reiterated a “buy” rating and issued a $24.50 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday. B. Riley upgraded Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $19.00 in a research note on Thursday, September 6th. William Blair reiterated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $25.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. Finally, Jefferies Financial Group lifted their price objective on Arrowhead Pharmaceuticals to $24.00 and gave the stock a “buy” rating in a research note on Friday, September 14th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $44.86.
Get Arrowhead Pharmaceuticals alerts:

Shares of Arrowhead Pharmaceuticals stock traded down $0.11 during trading on Monday, reaching $14.21. The company’s stock had a trading volume of 235,649 shares, compared to its average volume of 1,321,183. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.37 and a current ratio of 6.37. The firm has a market capitalization of $1.32 billion, a PE ratio of -21.86 and a beta of 2.05. Arrowhead Pharmaceuticals has a one year low of $3.08 and a one year high of $22.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, December 11th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The business had revenue of $11.26 million for the quarter, compared to analyst estimates of $3.73 million. Arrowhead Pharmaceuticals had a negative return on equity of 57.18% and a negative net margin of 337.32%. Research analysts forecast that Arrowhead Pharmaceuticals will post 1.34 earnings per share for the current year.

In related news, CEO Christopher Richard Anzalone sold 90,000 shares of the business’s stock in a transaction dated Wednesday, December 12th. The stock was sold at an average price of $14.07, for a total transaction of $1,266,300.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Peter Brian Leone sold 131,137 shares of the business’s stock in a transaction dated Friday, October 19th. The shares were sold at an average price of $13.49, for a total value of $1,769,038.13. Following the transaction, the vice president now owns 160,000 shares in the company, valued at $2,158,400. The disclosure for this sale can be found here. Insiders sold 305,637 shares of company stock worth $4,246,343 over the last quarter. 4.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of ARWR. RTW Investments LP increased its stake in Arrowhead Pharmaceuticals by 184.6% during the second quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock valued at $112,874,000 after acquiring an additional 5,382,981 shares during the period. BlackRock Inc. increased its stake in Arrowhead Pharmaceuticals by 108.1% during the second quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock valued at $96,342,000 after acquiring an additional 3,679,986 shares during the period. FMR LLC bought a new position in Arrowhead Pharmaceuticals during the third quarter valued at about $37,922,000. Northern Trust Corp increased its stake in Arrowhead Pharmaceuticals by 380.1% during the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock valued at $14,464,000 after acquiring an additional 841,982 shares during the period. Finally, First Manhattan Co. increased its stake in Arrowhead Pharmaceuticals by 11.6% during the third quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock valued at $96,883,000 after acquiring an additional 523,675 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.
drulletje drie
0
$ 165.00 doe ik het wel voor ;)

RECRUITING ARO-ANG3 trouwens! Positief allemaal en met de slechte beursweken valt de koersdaling nog mee! Eindejaarsrally en we staan op de $ 20.00 ;)

clinicaltrials.gov/ct2/history/NCT037...
DeZwarteRidder
0
quote:

drulletje drie schreef op 2 januari 2019 09:24:


seekingalpha.com/article/4230817-arro...

Arrowhead heeft blijkbaar geen geneesmiddelen boven Fase 1 en dat vind ik zeer teleurstellend als je bedenkt hoelang dit bedrijf al bestaat.
drulletje drie
0
quote:

DeZwarteRidder schreef op 2 januari 2019 09:29:


[...]
Arrowhead heeft blijkbaar geen geneesmiddelen boven Fase 1 en dat vind ik zeer teleurstellend als je bedenkt hoelang dit bedrijf al bestaat.


arrowheadpharma.com/pipeline/
nelis h
0
2 PB's die doen vermoeden dat het met de longterm Tox wel snor zit:

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

ir.arrowheadpharma.com/press-releases
nelis h
0
KeepTHeFaith
0
Short interest een beetje gezakt met 1 mln. stukjes tot iets meer dan 17 mln. Blijft hoog. Gisteren nabeurs nog doorgestegen tot $13,97.
nelis h
0
quote:

KeepTHeFaith schreef op 26 januari 2019 12:44:


Gisteren nabeurs nog doorgestegen tot $13,97.


Met een stevig nabeurs volume van 550k
drulletje drie
0
quote:

nelis h schreef op 26 januari 2019 21:17:


[...]

Met een stevig nabeurs volume van 550k


Zelfs vandaag al voorbeurs handel dat is wel heel vroeg ;)
Volume van niets hoor maar goed.

www.nasdaq.com/symbol/arwr/premarket
2.405 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 117 118 119 120 121 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 23 okt 2020 21:59
Koers 58,870
Verschil +0,310 (+0,53%)
Hoog 59,035
Laag 57,350
Volume 1.351.364
Volume gemiddeld 1.510.981
Volume gisteren 1.245.894